Blood Diseases

HSCI research inspires startup

November 16, 2016

Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders

Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases...

Read more about HSCI research inspires startup

Harvard-led researchers offer potential new treatments for subtype of acute myeloid leukemia

December 23, 2013

An international team of researchers working in the Boston and Singapore labs of Harvard Stem Cell Institute (HSCI) Blood Program leader Daniel Tenen, MD, recently identified new candidates for the treatment of an acute myeloid leukemia (AML) subtype caused by mutations of CEBPA, a tumor suppressor. The findings were published in two separate studies:... Read more about Harvard-led researchers offer potential new treatments for subtype of acute myeloid leukemia

Pages